Breaking News, Financial News

Financial Report: Hospira

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 2Q Revenues: $671 million (+1%) 2Q Earnings: $54 million (-25%) YTD Revenues: $1.3 billion (+1%) YTD Earnings: $134 million (-10%) Comments: R&D expense rose 19% percent in the quarter to $39 million. S,G&A expense in the quarter was $111 million, or 17% of sales, compared with $87 million, or 13% of sales in 2Q2005. The company completed its legal separation from Abbott in the quarter, including the transition of the remaining countries to Hospira....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters